Inhibrx Biosciences, Inc. 8K

Inhibrx Biosciences used an 8-K to furnish an investor presentation detailing strong interim INBRX-106 clinical data and a planned Phase 2 expansion aimed at supporting potential accelerated approval in HPV-positive head and neck cancer and broader tumor and vaccine combinations.

Inhibrx Biosciences, Inc. furnished an investor presentation on its investigational OX40 agonist INBRX-106, highlighting interim Phase 2 data from the HexAgon-HN trial in first-line recurrent/metastatic head and neck squamous cell carcinoma showing substantially higher objective response rates, complete response rates, and progression-free survival when INBRX-106 is combined with pembrolizumab versus pembrolizumab alone—particularly in HPV-positive patients—and outlining a plan to amend and expand the Phase 2 portion of the study by approximately 50 additional HPV-positive patients to support a potential accelerated approval pathway by late 2028 or early 2029, as well as broader expansion strategies into other highly immunogenic and virally driven tumors and combinations with individualized neoantigen cancer vaccines.

Filing Facts

CIK

2007919

Ticker

INBX

Form

8K

Source Type

fda

Accession

0002007919-26-000047

Alert Tier

6